

© 2019 The Authors. Orthopaedic Surgery published by Chinese Orthopaedic Association and John Wiley & Sons Australia, Ltd.

REVIEW ARTICLE

Long-term Results Comparing Cervical Disc Arthroplasty to Anterior Cervical Discectomy and Fusion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Qiao-li Wang, RN^{1†}, Zhi-ming Tu, MD^{2,3†}, Pan Hu, MD, PhD^{3,4†}, Filippos Kontos, MD³, Ya-wei Li, MD, PhD², Lei Li, MD², Yu-liang Dai, MD, PhD², Guo-hua Lv, MD, PhD², Bing Wang, MD, PhD²

¹ICU Center and ²Department of Spine Surgery, The Second Xiangya Hospital of Central South University, Changsha and ⁴Department of Orthopaedic Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, China and ³Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Objective: Whether cervical disc arthroplasty (CDA) is superior to anterior cervical discectomy and fusion (ACDF) remains controversial, especially in relation to long-term results. The present study aimed to evaluate the long-term safety and efficiency of CDA and ACDF for cervical disc disease.

Methods: We performed this study according to the Cochrane methodology. An extensive search was undertaken in PubMed, Embase, and Cochrane databases up to 1 June 2019 using the following key words: "anterior cervical fusion," "arthroplasty," "replacement" and "artificial disc". RevMan 5.3 (Cochrane, London, UK) was used to analyze data. Safety and efficiency outcome measures included the success rate, functional outcome measures, adverse events (AE), adjacent segment degeneration (ASD), secondary surgery, and patients' satisfaction and recommendation rates. The OR and MD with 95% confidence interval (CI) were used to evaluate discontinuous and continuous variables, respectively. The statistically significant level was set at P < 0.05.

Results: A total of 11 randomized controlled trials with 3505 patients (CDA/ACDF: 1913/1592) were included in this meta-analysis. Compared with ACDF, CDA achieved significantly higher overall success (2.10, 95% *CI* [1.70, 2.59]), neck disability index (NDI) success (1.73, 95% *CI* [1.37, 2.18]), neurological success (1.65, 95% *CI* [1.24, 2.20]), patients' satisfaction (2.14, 95% *CI* [1.50, 3.05]), and patients' recommendation rates (3.23, 95% *CI* [1.79, 5.80]). Functional outcome measures such as visual analog score neck pain (–5.50, 95% *CI* [–8.49, –2.52]) and arm pain (–3.78, 95% *CI* [–7.04, –0.53]), the Short Form-36 physical component score (SF-36 PCS) (1.93, 95% *CI* [0.53, 3.32]), and the Short Form-36 mental component score (SF-36 MCS) (2.62, 95% *CI* [0.95, 4.29]), revealed superiority in the CDA group. CDA also achieved a significantly lower rate of symptomatic ASD (0.46, 95% *CI* [0.34, 0.63]), total secondary surgery (0.50, 95% *CI* [0.29, 0.87]), secondary surgery at the index level (0.46, 95% *CI* [0.29, 0.74]), and secondary surgery at the adjacent level (0.37, 95% *CI* [0.28, 0.49]). However, no significant difference was found in radiological success (1.35, 95% *CI* [0.88, 2.08]), NDI score (–2.88, 95% *CI* [–5.93, 0.17]), total reported AE (1.14, 95% *CI* [0.92, 1.42]), serious AE (0.89, 95% *CI* [0.71, 1.11]), device/surgery-related AE (0.90, 95% *CI* [0.68, 1.18]), radiological superior ASD (0.63, 95% *CI* [0.28, 1.43]), inferior ASD (0.45, 95% *CI* [0.19, 1.11]), and work status (1.33, 95% *CI* [0.78, 2.25]). Furthermore, subgroup analysis showed different results between US and non-US groups.

Conclusion: Our study provided further evidence that compared to ACDF, CDA had a higher long-term clinical success rate and better functional outcome measurements, and resulted in less symptomatic ASD and fewer

Address for correspondence Bing Wang, MD, PhD, Department of Spine Surgery, The Second Xiangya Hospital of Central South University, 139 Renmin Road, Changsha, Hunan, China 410011 Tel: (86)0731-85295825; Fax: (86)0731-85295825; Email: xywb801@csu.edu.cn †These authors contributed equally to this work.

Received 9 October 2019; accepted 6 November 2019

secondary surgeries. However, worldwide multicenter RCT with long-term follow up are still needed for further evaluation in the future.

Key words: Adjacent segment degeneration; Anterior cervical discectomy and fusion; Cervical disc arthroplasty; Cervical disc disease; Long-term

Introduction

nterior cervical discectomy and fusion (ACDF) has been Aviewed as the gold standard procedure for cervical disc disease (CDD), including radiculopathy and myelopathy. A recent survey revealed that 84.3% of surgeons performed ACDF as the standard technique for CDD¹. Even though successful clinical outcomes can be achieved with ACDF. postoperative complications such as pseudoarthrosis or nonunion, instrument failure, and adjacent segment degeneration (ASD) have been the greatest concerns²⁻⁴. Cervical fusion could lead to loss of range of motion at the index level and shift load to the adjacent level, then result in accelerating ASD^{2,3,5}. Hilibrand et al. reported that annually 2.9% of the patients underwent anterior interbody fusion will most likely develop ASD requiring cervical intervention². Thus, spinal surgeons have been attempting to find an alternative procedure to avoid these complications associated with ACDF.

A motion-preserving procedure, cervical disc arthroplasty (CDA), seems to be a good choice. CDA was initially designed using motion-preserving techniques to restore cervical physiologic biomechanical properties and alleviate the adjacent-level loads, and eventually reduces or eliminates the risk of developing ASD⁶. Clinical data showed that preoperative motion could be maintained in the long run following CDA⁷. Promisingly, recent studies have proved that CDA is cost-effective and is comparable to ACDF in long-term follow ups^{8–11}. However, some disadvantages of CDA cannot be overlooked, such as heterotopic ossification, implant failure, and bone loss^{12–14}. In addition, the revision burden of CDA was two times higher than that of ACDF¹⁵.

In the past 20 years, a series of randomized controlled trials (RCT) have been conducted; however, the reported results are inconsistent and have great variability. Although a few systematic reviews have been performed, researchers have failed to reach an agreement owing to varied criteria^{5,16–24}. Nevertheless, there is an absence of pooling of long-term results in a comprehensive meta-analysis. Therefore, this is the first study aiming at comparing CDA to ACDF with special focus on long-term safety and efficiency. The conclusions drawn from this study could provide solid evidence for the future application of CDA.

This study was approved by the Ethics Committee of The Second Xiangya Hospital of Centeral South University.

Methods

Literature Search Strategy

We followed the Cochrane methodology guidelines to perform this meta-analysis and searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CCRCT)

databases up to 1 June 2019. The keywords "anterior cervical fusion," "arthroplasty," "replacement," and "artificial disc" combined with "and/or" were used to identify any relevant studies.

Inclusion and Exclusion Criteria

The inclusion criteria were as follows: (i) patients ≥ 18 years old with symptomatic CDD presenting with radiculopathy and/or myelopathy; (ii) participants were treated with either CDA or ACDF; (iii) comparison was performed between CDA and ACDF; (iv) at least one efficiency and safety outcome measurement was available; and (v) prospective RCT with a follow up ≥ 5 years.

Articles that met the following characteristics were excluded: (i) reviews, case reports or series, editorials, conference abstracts, and retrospective studies; (ii) duplicated data publications from the same RCT; (iii) partial results with insufficient data; and (iv) non-English publications.

Literature Screening

Literature screening was performed by two independent investigators (Tu, ZM and Wang, QL). Any disagreement was discussed with another author (Hu, P) to reach consensus. After excluding duplicates, literature selection was carried out according to the inclusion and exclusion criteria based on title and abstract. Then, extensive screening of full-text articles was performed. All RCT that compared the long-term efficiency and safety of CDA and ACDF for CDD were included.

Quality Assessment of the Included Studies

Quality assessment was achieved using the criteria recommended by the Cochrane Back Review Group criteria²⁵. The types of biases assessed are: four selection bias, four performance bias, two attrition bias, one detection bias, and one reporting bias. The articles scoring at least 6 of these 12 biases were considered as at low risk of bias. The last bia assessed is "Other," defined as any potential bias not detected using the previous criteria.

Data Extraction

Data extraction was performed as follows: (i) general characteristics such as first author, year of publication, number of clinical trial (NCT), enrolled patients, follow-up rate, age, sex, surgical levels, type of prosthesis, and follow-up duration were extracted; and (ii) outcome measures, including clinical success rate (overall success, NDI success, neurological success, and radiological success), functional outcome

measurements (NDI score, visual analog score [VAS] neck pain and arm pain, and SF-36 PCS and MCS), AE (total reported AE, serious AE and device/surgery-related AE), ASD (symptomatic ASD, radiological superior or inferior ASD), secondary surgery (total secondary surgery, secondary surgery at the index level and at the adjacent level), work status, and patients' satisfaction and recommendation rates were extracted. This task was performed by two independent investigators (Tu, ZM and Wang, QL), who extracted the data and discussed any disagreement to reach consensus with a third investigator (Hu, P). Data-extracting software was used to obtain data from figures when original data was not available ²⁶.

Statistical Analysis

RevMan 5.3 (Cochrane, London, UK) was used to pool extracted data into a combined analysis. The odds ratio (OR) and mean difference (MD) with 95% confidence intervals (CI) were used to evaluate discontinuous and continuous variables, respectively. Heterogeneity was assessed using a χ^2 -test and an I^2 -test. A fixed effects model was used when $I^2 < 50\%$; otherwise, a random effects model was used. Sensitivity analysis was performed by comparing two different effects models.

If the statistical difference changed, the leave-one-out method²⁷ and subgroup analysis was performed to find the origin of heterogeneity. Funnel plots were applied to assess for publication bias. A statistically significant difference was defined as a *P*-value of less than 0.05.

Results

Literature Review

Initial database searching identified 1954 articles (PubMed: 650, Embase: 1020, CCRCT: 284) and detailed literature screening is described in the flow diagram in Figure 1. A total of 814 studies were removed because they were duplicates, 1076 studies were excluded based on their titles and abstracts, and 43 studies were excluded for other reasons. As a result, 21 studies^{28–48} were included for further evaluation. Among them, 2 studies^{45,47} were partial results of multicenter RCT and 8 studies^{39–44,46,48} included duplicated data for publication. Ultimately, 11 articles^{28–38} involving 3505 patients (CDA/ACDF: 1913/1592) were included in this meta-analysis. There are 923 male and 990 female patients in the CDA group and 791 male and 801 female patients in the ACDF group. The mean age of each included population varies from 40 to




Fig. 1 Flow diagram for study selection.

50 years in both groups. All the patients suffered from radiculopathy and/or myelopathy caused by cervical disc disease with C_{3-4} to C_{6-7} involvement. The basic characteristics of the included studies and patients are summarized in Table 1. Among them, 8 studies ^{28–30,32–34,36,38} compared single-level CDD, 1 study ³¹ compared two-level CDD, and 2 studies ^{35,37} compared both single-level and two-level CDD independently.

Quality Assessment of the Included Studies

Methodological quality assessment of the 11 eligible studies is shown in Fig. 2. Nine studies^{28,30-37} were adequately randomized, but 1 study²⁹ did not provide detailed information of randomization, and 1 study³⁸ failed to achieve adequate randomization. Only 4 studies 30,32,33,35 provided a clear statement regarding avoiding allocation concealment. In addition, all included RCT²⁸⁻³⁸ failed to achieve blinding to patients and care providers due to the specialty of this kind of trial. The patients were informed immediately after surgery about the type of surgical procedure they had been underwent, and care providers were aware of which kind of surgery was to be performed during surgery^{28,30-37}. Almost all the studies described the dropout rate and 2 studies^{28,29} with a followup rate below 70% were considered as having high risk of bias. All included studies were scored above seven and were rated as having low risk of bias.

Heterogeneity Analysis

Of all the parameters identified for meta-analysis, 6 studies compared overall success^{28,29,31,34,37,38} and NDI success^{28,31,34,36-38}, 7 studies compared neurological success^{28,31,33,34,36-38}, 3 studies compared radiological success^{31,36,37}, 7 studies compared NDI score^{28,32,33,35-38}, 5 studies compared neck pain score^{33,35-38}, 4 studies compared arm pain score ^{33,35-37}, 5 studies compared SF-36 PCS^{28,30,33,36,38}, 4 studies compared SF-36 MCS^{30,33,36,38}, 8 studies compared any AE^{28-31,33,36-38}, 4 studies compared serious AE^{31,36-38}, 6 studies compared device/surgery-related AE^{29,31,33,36-38} and symptomatic ASD^{30,33-35,37,38}, 2 studies compared radiological superior and inferior ASD^{37,38}, 8 studies compared total secondary surgeries^{28-30,32,33,35-37} and secondary surgeries at the index level^{28,30,31,33,35-38}, 9 studies compared secondary surgeries at the adjacent level^{28,30,31,33-38}, 2 studies compared work status^{28,34}, 4 studies compared patients' satisfaction rate^{31,36-38}, and 2 studies compared patients' recommendation rate^{36,37}.

The heterogeneity test showed that $I^2 < 50\%$ for overall success, NDI success, neurological success, radiological success, VAS neck pain and arm pain, SF-36 PCS and MCS, total reported AE, serious AE, device/surgery-related AE, symptomatic ASD, secondary surgery at the adjacent level, and patients' satisfaction and recommendation rates. This indicates that there is low heterogeneity among these parameters and a fix effects model could be applied for combined statistics. In contrast, the heterogeneity test showed $I^2 > 50\%$ for NDI score, radiological superior and inferior ASD, total secondary surgery, secondary surgery at the index level, and work status, which indicates significant or large

	Follow Level Prosthesis up	1 Prestige ST 7 years 1 Kineflex C 5 years	1 Bryan 9 years	2 Prestige LP 10 years	1 Mobi-C 5 years	54) 1 ProDisc-C 7 years	1 BRYAN 10 years	1-2 Discover 5 years	1 PCM 5 years	1 Mobi-C 7 years	2 Mobi-C 7 years	1 SECURE-C 7 years
	BMI (CDA/ACDF)	/ 27.5(5.0)/28.7(5.7)	/	28.2(5.6)/28.6(4.9)	21(3.2)/22(2.5)	26.44(5.32)/27.34(5.54)	26.6(4.8)/27.6(5.0)	26/26	28.2(4.6)/27.4(4.8)	27.3 (4.4)/27.4 (4.2)	27.6(4.5)/28.1(4.2)	28.9(5.53)/29.0(5.47)
	Sex (female)	148/142 74/74	26/22	117/98	30/28	55/54	132/108	42/33	105/89	78/36	113/45	70/72
	Age (CDA/ACDF)		44.1(6.4)/43.1(7.5)	47.1(8.3)/47.3(7.7)	46.3(7.8)/48.5(8.3)	42.1(8.42)/43.5(7.15)	44.4/44.7	46.9 (6.8)/47.0 (6.9)	49.3(5.0)/43.7(8.3)	43.3(9.2)/44.0(8.2)	44.3(8.1)/46.2(8.0)	43.4(7.50)/44.4(7.86)
	Enrolled patients Follow-up rate (CDA/ACDF) (CDA/ACDF)	76.8%/69.1% 43.3/43.9 68.4%/62.4% 43.7(7.76),	%6'.26/%0'.86	86.0%/84.9%	91.1%/94.1%	92%/92%	100%/100%	89.2%/87.1	74.8%/70.3%	80.1%/74.3%	84.4%/75%	86.1%/84.2%
	Enrolled patients (CDA/ACDF)	276/265 136/133	50/47	209/188	56/51	103/106	242/221	83/10	218/185	164/81	225/105	151/140
	Design	RCT, 31-sites RCT, 21-sites	RCT, single-site	RCT, 30-sites	RCT, single-site	RCT, 13-sites	RCT, 38-sites	RCT, 3-sites	RCT, 24-sites	RCT, 24-sites	RCT, 24-sites	RCT, 18-sites
uded studies	Number of clinical trial	NCT00642876 NCT00374413	Netherlands ISRCTN41681847	NCT00637156	Unknown	NCT00291018	NCT00437190	ISRCTN44347115	Unknown	NCT00389597	NCT00389597	Unknown
istics of incl	Region	USA USA	Netherlands	NSA	China	U.S.	NSA	Sweden	NSA	NSA	NSA	NSA
TABLE 1 Characteristics of included studies	Study	Burkus 2014 ²⁸ Coric 2018 ²⁹	Donk 2017 ³⁰	Gornet 2019 ³¹	Hou 2016^{32}	Janssen 2015^{33}	Lavelle 2018 ³⁴	MacDowall 2019 ³⁵	Phillips 2015 ³⁶	Radcliff 2017a ^{37*}	Radcliff 2017b ^{37*}	Vaccaro 2018 ³⁸

	Adequate randomization	Allocation concealment	Blinding of patients	Blinding of care provider	Blinding of outcome assessment	Acceptable drop-out rate	Intention-to-treat analysis	Free of selective reporting	Similar baseline data	Avoid or simar cointervention	Acceotable compliance	Timing of assessment	Other bias
Burkus (2014)	+	?		?	?	+		+	+	+	+	+	+
Coric (2018)	?	?	?	?	+			+	+	+	+	+	+
Donk (2017)	+	+	?		?	+	+	+	+	+	+	+	+
Gornet (2019)	+	?			+	+	+	+	+	+	+	+	+
Hou (2017)	+	+			+	+			+	+	+	+	+
Janssen (2015)	+	+			?	+		+		+	+	+	+
Lavelle (2018)	+	?	-	-	?		-	+	-	+	+	+	+
MacDowall (2019)	+	+	-	-	+	+	+	+	+	+	+	+	•
Phillips (2015)	+	?	-	-	•	+	+	+	+	+	+	+	+
Radcliff (2017)	+	?			?	+	-	+	+	+	+	+	•
Vaccaro (2018)	-	?	?	?	?	+	-	+	+	+	+	+	+

Fig. 2 Risk bias of included studies.

Outcome measurements	Included studies	Participants	l ²	Statistic effect model	Effect estimate	P-value
Overall success	6	1734	0%	OR (M-H, Fixed, 95% CI)	2.10 [1.70, 2.59]	<0.00001
NDI success	6	1972	20%	OR (M-H, Fixed, 95% CI)	1.73 [1.37, 2.18]	< 0.00001
Neurological success	7	1982	16%	OR (M-H, Fixed, 95% CI)	1.65 [1.24, 2.20]	0.0006
Radiological success	3	1002	0%	OR (M-H, Fixed, 95% CI)	1.35 [0.88, 2.08]	0.17
NDI score	7	1885	68%	MD (IV, Random, 95% CI)	-2.88 [-5.93, 0.17]	0.06
VAS neck pain	5	1366	33%	MD (IV, Fixed, 95% CI)	-5.50 [-8.49, -2.52]	0.0003
VAS arm pain	4	1134	0%	MD (IV, Fixed, 95% CI)	-3.78 [-7.04, -0.53]	0.02
SF-36 PCS	4	1149	0%	MD (IV, Fixed, 95% CI)	1.93 [0.53, 3.32]	0.007
SF-36 MCS	3	761	0%	MD (IV, Fixed, 95% CI)	2.62 [0.95, 4.29]	0.002
Total reported AE	8	2872	46%	OR (M-H, Fixed, 95% CI)	1.14 [0.92, 1.42]	0.22
Serious AE	4	1756	13%	OR (M-H, Fixed, 95% CI)	0.89 [0.71, 1.11]	0.29
Device/surgery-related AE	6	2317	2%	OR (M-H, Fixed, 95% CI)	0.90 [0.68, 1.18]	0.43
Symptomatic ASD	6	1628	29%	OR (M-H, Fixed, 95% CI)	0.46 [0.34, 0.63]	< 0.0000
Radiological superior ASD	2	659	83%	OR (M-H, Random, 95% CI)	0.63 [0.28, 1.43]	0.27
Radiological inferior ASD	2	474	78%	OR (M-H, Random, 95% CI)	0.45 [0.19, 1.11]	0.08
Total secondary surgery	8	2058	64%	OR (M-H, Random, 95% CI)	0.50 [0.29, 0.87]	0.01
Secondary surgery at the index level	8	2712	55%	OR (M-H, Random, 95% CI)	0.46 [0.29, 0.74]	0.001
Secondary surgery at the adjacent level	9	2937	18%	OR (M-H, Fixed, 95% CI)	0.37 [0.28, 0.49]	<0.0000
Work status	2	622	53%	OR (M-H, Random, 95% CI)	1.33 [0.78, 2.25]	0.29
Patients' satisfaction rate	4	1224	0%	OR (M-H, Fixed, 95% CI)	2.14 [1.50, 3.05]	< 0.0001
Patients' recommendation rate	2	727	0%	OR (M-H, Fixed, 95% CI)	3.23 [1.79, 5.80]	< 0.0001

AE, adverse event; ASD, adjacent segment degeneration; CI, confidence interval; MD, mean difference; NDI, neck disability index; OR, odds ratio; VAS, visual analog score.

heterogeneity. Therefore, a random effects model could be applied for combined statistics. The results of the heterogeneity test are summarized in Table 2.

Results of the Meta-Analysis


We pooled all extracted data comparing CDA with ACDF for CDD in this meta-analysis. The combined results are shown in Table 2 and Figs 3–8.

For clinical success rate, CDA showed significant superiority in overall success (OR = 2.10, 95% CI [1.70, 2.59], P < 0.00001, Fig. 3A), NDI success (OR = 1.73, 95% CI [1.37, 2.18], P < 0.00001; Fig. 3B), and neurological success (OR = 1.65, 95% CI [1.24, 2.20], P = 0.0006; Fig. 3C), while

no superiority was found in radiological success (OR = 1.35, 95% CI [0.88, 2.08], P = 0.17; Fig. 3D).

Functional outcome measurements showed superiority in CDA except for NDI score. The NDI score (WMD=-2.88, 95% CI [-5.93, 0.17]), P=0.06; Fig. 4A) was found to be lower in CDA without statistical difference. However, the combined results that favored CDA were identified in neck pain score (WMD=-5.50, 95% CI [-8.49, -2.52], P=0.0003; Fig. 4B), arm pain score (WMD=-3.78, 95% CI [-7.04, -0.53], P=0.02; Fig. 4C), SF-36 PCS (WMD=1.93, 95% CI [0.53, 0.32], 0.32


No superiority was showed in AE. Total reported AE $(OR = 1.14, 95\% \ CI \ [0.92, 1.42], P = 0.22, Fig. 5A)$, serious




	CDA	4	ACD	F		Odds ratio	Odds ratio	
Study or subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
Burkus (2014)	176	211	145	181	24.3%	1.25 [0.75, 2.09]		
Gornet (2019)	130	147	88	115	10.7%	2.35 [1.21, 4.56]		
Lavelle (2018)	114	126	78	103	7.7%	3.04 [1.44, 6.42]	_ 	
Phillips (2015)	128	160	89	128	18.6%	1.75 [1.02, 3.01]	-	
Radcliff (2017a)	137	162	67	79	13.1%	0.98 [0.46, 2.07]		
Radcliff (2017b)	187	224	73	104	15.5%	2.15 [1.24, 3.71]	_ -	
Vaccaro (2018)	111	125	90	107	10.2%	1.50 [0.70, 3.20]		
Total (95% CI)		1155		817	100.0%	1.73 [1.37, 2.18]	•	
Total events	983		630					
Hetetrogeneity: $\chi^2 = 7$.	50, df = 6	(P = 0.	28); $I^2 = 2$	20%		_ 		\dashv
Test for overall effects	Z = 4.60	(P < 0.	00001)			0.05	0.2 1 5	20
		`	,				Favors [CDA] Favors [ACDF]	
								$^{\circ}$

	CD	Δ.	ACD	F		Odds ratio	Odd	s ratio	
Study or subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M–H, Fix	ed, 95% CI	
Burkus (2014)	187	212	145	182	25.6%	1.91 [1.10, 3.31]			
Gornet (2019)	137	148	99	115	11.5%	2.01 [0.90, 4.52]			
Janssen (2015)	64	73	56	63	10.3%	0.89 [0.31, 2.54]	-	-	
Lavelle (2018)	116	126	98	103	11.9%	0.59 [0.20, 1.79]	-		
Phillips (2015)	146	158	112	128	13.1%	1.74 [0.79, 3.82]	-	-	
Radcliff (2017a)	109	123	46	52	10.2%	1.02 [0.37, 2.81]		_	
Radcliff (2017b)	176	188	68	82	8.4%	3.02 [1.33, 6.86]			
Vaccaro (2018)	116	124	92	105	8.9%	2.05 [0.81, 5.15]	-	-	
Total (95% CI)		1152		830	100.0%	1.65 [1.24, 2.20]		•	
Total events	1051		716						
Hetetrogeneity: $\chi^2 = 8$.32, df = 7	P = 0	.31); $I^2 = 1$	16%		⊢		 	\dashv
Test for overall effects	: Z = 3.43	(P < 0.	0006)			0.05		1 5	20
			,				Favors [CDA]	Favors [ACDF]	6

Fig. 3 Forest plot comparing clinical success rate between cervical disc arthroplasty (CDA) and anterior cervical discectomy and fusion (ACDF). (A) Overall success. (B) Neck disability index (NDI) success. (C) Neurological success. (D) Radiological success. *CI*, confidence interval.



LONG-TERM RESULTS COMPARING CDA AND ACDF



		CDA		Α	CDF			Mean difference	Mean differ	ence	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 9	5% CI	
Janssen (2015)	27.33	34	79	22.82	34.1	73	7.6%	4.51 [-6.33, 15.35]	-	_	
MacDowall (2019)	29.1	23.6	83	31.8	30.6	70	11.5%	-2.70 [-11.48, 6.08]			
Phillips (2015)	24.8	26.9	160	34.2	28.5	128	21.3%	-9.40 [-15.86, -2.94]			
Radcliff (2017a)	19	26.9	160	21.1	24.4	78	19.0%	-2.10 [-8.93, 4.73]	-		
Radcliff (2017b)	19	27.1	200	28.7	30.4	103	18.3%	-9.70 [-16.67, -2.73]	-		
Vaccaro (2018)	13.3	23.62	126	19.4	25.16	106	22.3%	-6.10 [-12.42, 0.22]	-		
Total (95% CI)			808			558	100.0%	-5.50 [-8.49, -2.52]	•		
Heterogeneity: $\chi^2 = 7$ Test for overall effect					%			⊢ -50	-25 0	25	
									Favors [CDA]	Favors [ACDF]	E

		CDA		Δ	CDF			Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Janssen (2015)	23.18	27.7	79	22.17	30.6	73	12.2%	1.01 [-8.30, 10.32]	
MacDowall (2019)	24	22.8	83	23.8	28.1	70	15.7%	0.20 [-8.01, 8.41]	
Phillips (2015)	25.3	27.6	160	31.7	29.5	128	23.9%	-6.40 [-13.06, 0.26]	
Radcliff (2017a)	12.8	23.3	160	20.9	27.1	78	21.6%	-8.10 [-15.11, -1.09]	
Radcliff (2017b)	15.9	25.7	200	18.4	27	103	26.6%	-2.50 [-8.81, 3.81]	-
Total (95% CI)			682			452	100.0%	-3.78 [-7.04, -0.53]	•
Heterogeneity: $\chi^2 = 4$					%			⊢ -50	-25 0 25 50
Test for overall effect	s:∠=2.	28 (P	= 0.02))				_30	Favors [CDA] Favors [ACDF]

		CDA		A	CDF			Mean Difference	Mean Difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Burkus (2014)	45.1	12	209	43.2	12.1	179	33.7%	1.90 [-0.51, 4.31]	-
Donk (2017)	78.5	58.8	49	82.2	56.9	46	0.4%	-3.70 [-26.97, 19.57]	
Janssen (2015)	46.74	11.8	79	47.29	12	73	13.6%	-0.55 [-4.34, 3.24]	+
Phillips (2015)	46.5	10.4	156	43.2	11.2	127	30.2%	3.30 [0.76, 5.84]	-
Vaccaro (2018)	46.4	12.07	125	44.7	10.9	106	22.2%	1.70 [-1.26, 4.66]	 -
Total (95% CI)			618			531	100.0%	-1.93 [0.53, 3.32]	•
Heterogeneity: $\chi^2 = 3$,			F0	05 0 05 50
Test for overall effect	ts: Z = 2.	70 (P:	= 0.007	7)				-50	
				•					Favors [CDA] Favors [ACDF]

		CDA		A	CDF			Mean difference	Mean difference	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	I IV, Random, 95% CI	
Donk (2017)	81.6	70.5	49	88	45.8	46	0.5%	-6.40 [-30.17, 17.37]		
Janssen (2015)	49.53	12.5	79	46.83	12.2	73	18.0%	2.70 [-1.23, 6.63]	l -	
Phillips (2015)	52	9.3	156	48.2	11.2	127	46.9%	3.80 [1.37, 6.23]	■	
Vaccaro (2018)	52.1	10.47	125	51	11.35	106	34.6%	1.10 [-1.74, 3.94]	†	
Total (95% CI)			409			352	100.0%	2.62 [0.95, 4.29]	•	
Heterogeneity: $\chi^2 = 2$	2.56, df =	3 (P =	0.46)	$I^2 = 0\%$	6					-
Test for overall effect	s: $Z = 3$.	08 (P =	= 0.002	2)						50
				,					Favors [CDA] Favors [ACDF]	Œ

Fig. 4 Forest plot comparing functional outcome measurements between cervical disc arthroplasty (CDA) and anterior cervical discectomy and fusion (ACDF). (A) Neck disability index (NDI) score. (B) Visual analog score (VAS) neck pain. (C) VAS arm pain. (D) Short Form-36 physical component score (SF-36 PCS). (E) Short Form-36 mental component score (SF-36 MCS). CI, confidence interval.


AE (OR = 0.89, 95% CI [0.71, 1.11], P = 0.29, Fig. 5B), and device/surgery-related AE (OR = 0.90, 95% CI [0.68, 1.18], P = 0.43; Fig. 5C) were similar between CDA and ACDF.

As for ASD, the incidence of symptomatic ASD (OR = 0.46, 95% CI [0.34, 0.63]), P < 0.00001; Fig. 6A) was significantly lower in CDA; however, radiologically superior ASD (OR = 0.63, 95% CI [0.28, 1.43], P = 0.27; Fig. 6B) and inferior ASD (OR = 0.45, 95% CI [0.19, 1.11], P = 0.08; Fig. 6C) were not significantly different between groups.

Strikingly, when compared to ACDF, our results revealed that CDA had significant superiority in total secondary surgery (OR = 0.50, 95% CI [0.29, 0.87], P = 0.01, Fig. 7A), secondary surgery at the index level (OR = 0.46, 95% CI [0.29, 0.74], P = 0.001, Fig. 7B), and secondary surgery at the adjacent level (OR = 0.37, 95% CI [0.28, 0.49], P < 0.00001; Fig. 7C).

Finally, work status (OR = 1.33, 95% CI [0.78, 2.25], P = 0.29, Fig. 8A) was similar at the last follow up between CDA and ACDF. CDA achieved a higher rate of patient satisfaction (OR = 2.14, 95% CI [1.50, 3.05], P = 0.0002; Fig. 8B)


LONG-TERM RESULTS COMPARING CDA AND ACDF



	CD	A	ACD	F		Odds ratio	Odds ra	tio	
Study or subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 9	5% CI	
Gornet (2019)	124	209	120	188	31.6%	0.83 [0.55, 1.24]			
Phillips (2015)	91	214	74	190	27.7%	1.16 [0.78, 1.73]			
Radcliff (2017a)	10	167	3	81	2.3%	1.69 [0.45, 6.31]		•	
Radcliff (2017b)	12	225	6	105	7.1%	0.60 [0.25, 1.47]			
Vaccaro (2018)	87	236	65	144	31.3%	0.71 [0.47, 1.08]			
Total (95% CI)		1048		708	100.0%	0.89 [0.71, 1.11]	•		
Total events	324		271						
Heterogeneity: $\chi^2 = 4$.	57, df = 4 (F	9 = 0.33	$I^2 = 13\%$			⊢			$\overline{}$
Test for overall effects	Z = 1.06 (F	P = 0.29)			0.02	0.1 1	10	50
							Favors [CDA]	Favors [ACDF]	
									B


Odds ratio CDA Odds ratio ACDE Weight Total M-H, Fixed, 95% CI M-H. Fixed, 95% CI Study or subgroup Events 53 1.23 [0.76, 1.99] Coric (2018) 27.4% 61 133 14 Gornet (2019) 209 188 13.2% 0.43 [0.17, 1.09] 103 242 214 30 11 16 Janssen (2015) Lavelle (2018) 20.0% 10 13 221 10.2% 0.82 [0.34, 1.98] Phillips (2015) Radcliff (2017a 11.8% 3.5% 10.8% 0.70 [0.33, 1.50] 1.69 [0.45, 6.31] 190 164 10 6 81 Radcliff (2017b) 12 225 105 0.60 [0.25, 6.47] Total (95% CI) 1293 1024 100.0% 0.90 [0.68, 1.18] 141 136 Total events Heterogeneity: y = 6.11, df = 6 (P = 0.41); I² = 2% 0.02 0.1 10 50 Test for overall effects: Z = 0.79 (P = 0.43) Favors [experimental] Favors [control]

Fig. 5 Forest plot showing a comparison of the frequency of adverse events (AE) between cervical disc arthroplasty (CDA) and anterior cervical discectomy and fusion (ACDF). (A) Total reported AE. (B) Serious AE. (C) Device/surgery-related AE. *CI*, confidence interval.




	CDA	١.	ACD	F		Odds ratio	Odds ratio	
Study or subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	
Phillips (2015)	48	145	54	106	34.9%	0.48 [0.28, 0.80]		
Radcliff (2017a)	42	104	28	43	30.4%	0.36 [0.17, 0.76]		
Radcliff (2017b)	57	152	33	109	34.7%	1.38 [0.82, 2.33]	+-	
Total (95% CI)		401		258	100.0%	0.63 [0.28, 1.43]		
Total (events)	147		115					
Heterogeneity: $\tau^2 = 0$	$.42; \chi^2 = 11.0$	63, df =	2(P = 0.	.003); 12	= 83%			
Test for overall effects	Z = 1.10 (F	P = 0.27	7)			0.02	0.1 1 10 Favors [CDA] Favors [ACDF]	50 (

Fig. 6 Forest plot comparing the incidence of adjacent segment degeneration (ASD) between cervical disc arthroplasty (CDA) and anterior cervical discectomy and fusion (ACDF). (A) Symptomatic ASD. (B) Radiological superior ASD. (C) Radiological inferior ASD. *CI*, confidence interval.



LONG-TERM RESULTS COMPARING CDA AND ACDF



	C	DA	AC	DF		Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Burkus (2014)	11	276	29	265	14.6%	0.34 [0.17, 0.69]	
Donk (2017)	0	50	5	47	2.4%	0.08 [0.00, 1.42]	
Gornet (2019)	9	209	18	188	13.2%	0.42 [0.19, 0.97]	
Janssen (2015)	6	103	16	106	11.3%	0.35 [0.13, 0.93]	
MacDowall (2019)	15	67	3	51	8.3%	4.62 [1.26, 16.94]	
Phillips (2015)	17	211	24	184	15.5%	0.58 [0.30, 1.13]	
Radcliff (2017a)	5	164	5	81	8.5%	0.48 [0.13, 1.70]	1
Radcliff (2017b)	10	225	11	105	12.4%	0.40 [0.16, 0.97]	
Vaccaro (2018)	10	236	22	144	13.8%	0.25 [0.11, 0.53]	
Total (95% CI)		1541		1171	100.0%	0.46 [0.29, 0.74]	•
Total events	83		133				
Heterogeneity: $\tau^2 = 0.2$	$27, \chi^2 = 17.6$	8, df = 8	B (P = 0.0)	2); $I^2 = $	55%	_	
Test for overall effects:	Z = 3.22 (I	P = 0.00	11)	**		C	0.01 0.1 1 10 100
	,. <u></u> (.		,				Favors [CDA] Favors [ACDF]
							B

	C	DA	AC	DF		Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	I M-H, Fixed, 95% CI
Burkus (2014)	11	276	24	265	14.8%	0.42 [0.20, 0.87]]
Donk (2017)	1	50	1	47	0.6%	0.94 [0.06, 15.45]	1 -
Gornet (2019)	16	209	24	188	14.7%	0.57 [0.29, 1.10]]
Janssen (2015)	6	103	13	106	7.6%	0.44 [0.16, 1.21]]
Lavelle (2018)	12	124	16	101	10.1%	0.57[0.26, 1.27]	1 -+
MacDowall (2019)	5	67	5	51	3.3%	0.74 [0.20, 2.71]]
Phillips (2015)	1	211	19	184	12.7%	0.04 [0.01, 0.31]]
Radcliff (2017a)	6	164	11	81	9.0%	0.24 [0.09, 0.68]]
Radcliff (2017b)	10	225	12	105	9.9%	0.36 [0.15, 0.86]]
Vaccaro (2018)	10	236	23	144	17.3%	0.23 [0.11, 0.51]]
Total (95% CI)		1665		1272	100.0%	0.37 [0.28, 0.49]	•
Total events	78		148				
Heterogeneity: $\chi^2 = 11$.	00, df = 9 (P = 0.28	8); $I^2 = 18^\circ$	%			
Test for overall effects:	Z = 6.79 (o.00	0001)				0.01 0.1 1 10 100
			,				Favors [CDA] Favors [ACDF]

Fig. 7 Forest plot showing a comparison of secondary surgery rate between cervical disc arthroplasty (CDA) and anterior cervical discectomy and fusion (ACDF). (A) Total secondary surgery. (B) Secondary surgery at the index level. (C) Secondary surgery at the adjacent level. *CI*, confidence interval.

and patients' recommendation (OR = 3.23, 95% CI [1.79, 5.80], P < 0.00001; Fig. 8C).

Sensitivity Analysis

Combined OR or MD with 95% CI using fixed and random effects for all outcome measures are showed in Table 3. The consistency of the combined results was identified in overall success, NDI success, neurological success, radiological success, VAS neck pain and arm pain, SF-36 PCS and MCS, total reported AE, serious AE, device/surgery-related AE, symptomatic ASD, total secondary surgery, secondary surgery at the index level and at the adjacent level, and patients' satisfaction and recommendation rates. This means that these results are stable and reliable. However, the situation was quite different for NDI score, and radiological superior and inferior ASD, indicating that the combined results were unreliable. Therefore, further analysis was performed.

Then, we performed sensitivity analysis based on the leave-one-out method²⁷. For NDI score, we found that the combined result changed significantly when removing the study from Hou et al.³² or MacDowall et al.³⁵, with the Pvalue reduced from 0.06 to 0.02. Thus, we performed a subgroup analysis (Table 4) and found that the heterogeneity was 40% and 0% in the US and non-US subgroups, respectively, indicating that the heterogeneity originated from the studies from different regions. In addition, for radiological superior ASD, after we excluded the data from Radicliff et al. $(2017)^{37}$, I^2 decreased from 83% to 0%, and the statistical significance changed. For radiological inferior ASD, after we excluded the study from Phillips et al.36, I2 decreased from 78% to 28%, and the statistical significance also changed. This indicates that they were the source of heterogeneity for radiological superior and inferior ASD, respectively.

LONG-TERM RESULTS COMPARING CDA AND ACDF




Fig. 8 Forest plot comparing work status (A), patients' satisfaction (B), and patients' recommendation (C) between cervical disc arthroplasty (CDA) and anterior cervical discectomy and fusion (ACDF). *CI*, confidence interval.

	CI	DA	AC	DF		Odds ratio	Odds ratio	
Study or subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
Phillips (2015)	151	160	108	127	55.4%	2.95 [1.29, 6.77]	-	
Radcliff (2017a)	127	132	48	54	21.1%	3.17 [0.93, 10.89]		
Radcliff (2017b)	179	185	61	69	23.6%	3.91 [1.31, 11.73]		
Total (95% CI)		477		250	100.0%	3.23 [1.79, 5.80]	•	
Total events	457		217					
Heterogeneity: $\chi^2 = 0.16$	6 df = 2 (P = 1)	= 0.92);	$I^2 = 0\%$			<u> </u>		
Test for overall effects: 2	Z = 3.91 (P)	< 0.000	01)			0.01	0.1 1 10 Favors [CDA] Favors [ACDF]	100

Subgroup Analysis

First, we performed subgroup analysis based on different regions. The included studies were classified into US and

non-US subgroups. The combined results of NDI score, symptomatic ASD, total secondary surgery, and secondary surgery at the index level and at the adjacent level are shown

	Fixed effects mo	odel	Random effects model		
Outcome measures	Effect estimated	P-value	Effect estimated	P-value	
Overall success	2.10 [1.70, 2.59]	<0.0001	2.10 [1.70, 2.59]	<0.0000	
NDI success	1.73 [1.37, 2.18]	<0.00001	1.73 [1.33, 2.26]	<0.0000	
Neurological success	1.65 [1.24, 2.20]	0.0006	1.64 [1.19, 2.27]	0.003	
Radiological success	1.35 [0.88, 2.08]	0.17	1.36 [0.87, 2.10]	0.17	
NDI score	-2.67 [-4.33, -1.01]	0.002	-2.88 [-5.93, 0.17]	0.06	
VAS neck pain	-5.50 [-8.49, -2.52]	0.0003	-5.21 [-8.91, -1.51]	0.006	
/AS arm pain	-3.78 [-7.04, -0.53]	0.02	-3.77 [-7.08, -0.46]	0.03	
SF-36 PCS	1.93 [0.53, 3.32]	0.007	1.93 [0.53, 3.32]	0.007	
SF-36 MCS	2.62 [0.95, 4.29]	0.002	2.62 [0.95, 4.29]	0.002	
Total reported AE	1.14 [0.92, 1.42]	0.22	1.12 [0.80, 1.55]	0.51	
Serious AE	0.89 [0.71, 1.11]	0.29	0.88 [0.69, 1.13]	0.32	
Device/surgery-related AE	0.90 [0.68, 1.18]	0.43	0.89 [0.67, 1.18]	0.42	
Symptomatic ASD	0.46 [0.34, 0.63]	< 0.00001	0.49 [0.32, 0.76]	0.001	
Radiological superior ASD	0.69 [0.50, 0.95]	0.02	0.63 [0.28, 1.43]	0.27	
Radiological inferior ASD	0.53 [0.36, 0.78]	0.001	0.45 [0.19, 1.11]	0.08	
Total secondary surgery	0.52 [0.39, 0.69]	< 0.00001	0.50 [0.29, 0.87]	0.01	
Secondary surgery at the index level	0.46 [0.34, 0.61]	< 0.00001	0.46 [0.29, 0.74]	0.001	
Secondary surgery in the adjacent level	0.37 [0.28, 0.49]	<0.00001	0.39 [0.28, 0.55]	<0.000	
Work status	1.28 [0.90, 1.82]	0.17	1.33 [0.78, 2.25]	0.29	
Patients' satisfaction rate	2.14 [1.50, 3.05]	<0.0001	2.14 [1.50, 3.06]	< 0.0001	
Patients' recommendation rate	3.23 [1.79, 5.80]	< 0.0001	3.25 [1.81, 5.82]	< 0.0001	

AE, adverse event; ASD, adjacent segment degeneration; CI, confidence interval; NDI, neck disability index; VAS, visual analog score.

LONG-TERM RESULTS COMPARING CDA AND ACDF

Outcome measurements		Included studies	Participants	l ²	Statistic effect model	Effect estimate	P-value
NDI score	US	6	1633	40%	MD (IV, Random, 95% CI)	-4.71 [-7.38, -2.04]	0.0005
	Non-US	2	252	0%	MD (IV, Fixed, 95% CI)	1.64 [-1.23, 4.51]	0.26
Symptomatic ASD	US	5	1413	0%	OR (M-H, Fixed, 95% CI)	0.40 [0.28, 0.58]	< 0.0000
	Non-US	2	215	68%	OR (M-H, Random, 95% CI)	0.42 [0.03, 5.57]	0.51
Total secondary surgery	US	5	1744	47%	OR (M-H, Fixed, 95% CI)	0.48 [0.35, 0.66]	< 0.0000
	Non-US	3	314	79%	OR (M-H, Random, 95% CI)	0.39 [0.04, 3.49]	=0.40
Secondary surgery at	US	7	2497	0%	OR (M-H, Fixed, 95% CI)	0.39 [0.29, 0.53]	<0.0000
the index level	Non-US	2	215	85%	OR (M-H, Random, 95% CI)	0.73 [0.01, 46.24]	=0.88
Secondary surgery at	US	8	2722	27%	OR (M-H, Fixed, 95% CI)	0.35 [0.26, 0.47]	<0.0000
the adjacent level	Non-US	2	215	0%	OR (M-H, Fixed, 95% CI)	0.77 [0.24, 2.51]	=0.67

ASD, adjacent segment degeneration; CI, confidence interval; MD, mean difference; NDI, neck disability index; OR, odds ratio.

in Table 4. Surprisingly, the combined results showed that CDA was superior to ACDF, with significant difference in all these outcome measures in the US subgroup. However, in the non-US subgroup, all these combined results were similar without statistical difference.

Second, we performed subgroup analysis based on the number of surgical levels. The combined results of overall success, neurological success, NDI success, radiological success, total reported AE, serious AE, device/surgery-related AE, secondary surgery at the index level and at the adjacent level, and patients' satisfaction rate are showed in Table 5. The combined results showed significantly less device/surgery-related AE of CDA in the two-level CDD group, with no statistical difference in single-level CDD. In contrast,

AE, adverse event; CI, confidence interval; NDI, neck disability index; OR, odds ratio

patients' satisfaction favored CDA in single-level CDD (P=0.0002), while in two-level CDD (P=0.05), further studies are needed to identify the superiority. The residual outcome measures are similar for single-level and two-level CDD.

Assessment of Publication Bias

The funnel plot was applied to detect publication bias. As for neurological success (Fig. 9A), the funnel plots appeared symmetric and all studies were included inside, indicating that no publication bias existed. However, for secondary surgery at the adjacent level (Fig. 9B), the funnel plots appeared symmetric and 1 study was not included inside, indicating that publication bias existed.

Outcome measureme	Included studies	Participants	l ²	Statistic effect model	Effect estimate 1.89 [1.47, 2.42]	<i>P</i> -value <0.00001	
verall success Single-level		5	1218	0%			OR (M-H, Fixed, 95% CI)
Overall Success	Two-level	2	516	0%	OR (M-H, Fixed, 95% CI)	2.70 [1.83, 4.00]	<0.00001
NDI success	Single-level	5	1382	27%	OR (M-H, Fixed, 95% CI)	1.55 [1.17, 2.05]	0.000
121 3400033	Two-level	2	590	0%	OR (M-H, Fixed, 95% CI)	2.23 [1.46, 3.40]	0.0002
Neurological success	Single-level	6	1449	9%	OR (M-H, Fixed, 95% CI)	1.46 [1.04, 2.03]	0.03
10410108.1	Two-level	2	533	0%	OR (M-H, Fixed, 95% CI)	2.44 [1.37, 4.34]	0.003
Radiological success	Single-level	2	470	0%	OR (M-H, Fixed, 95% CI)	1.68 [0.92, 3.05]	0.09
	Two-level	2	532	0%	OR (M-H, Fixed, 95% CI)	1.06 [0.56, 2.00]	0.87
Total reported AE	Single-level	7	2145	40%	OR (M-H, Fixed, 95% CI)	1.14 [0.91, 1.43]	0.24
	Two-level	2	727	79%	OR (M-H, Random, 95% CI)	1.34 [0.24, 7.49]	0.74
Serious AE	Single-level	3	1029	43%	OR (M-H, Fixed, 95% CI)	0.95 [0.72, 1.26]	0.72
	Two-level	2	727	0%	OR (M-H, Fixed, 95% CI)	0.79 [0.54, 1.14]	0.20
Device/surgery-related AE	Single-level	5	1590	0%	OR (M-H, Fixed, 95% CI)	1.02 [0.75, 1.38]	0.91
, 5:	Two-level	2	727	0%	OR (M-H, Fixed, 95% CI)	0.51 [0.27, 0.96]	0.04
Secondary surgery at	Single-level	6	1867	0%	OR (M-H, Fixed, 95% CI)	0.37 [0.26, 0.52]	<0.0000
the index level	Two-level	2	727	0%	OR (M-H, Fixed, 95% CI)	0.41 [0.22, 0.75]	0.004
Secondary surgery at	Single-level	7	2092	29%	OR (M-H, Fixed, 95% CI)	0.31 [0.22, 0.45]	<0.0000
the adjacent level	Two-level	2	727	0%	OR (M-H, Fixed, 95% CI)	0.48 [0.28, 0.82]	0.007
Patients' satisfaction rate	Single-level	3	705	0%	OR (M-H, Fixed, 95% CI)	2.48 [1.55, 3.96]	0.0002
	Two-level	2	519	12%	OR (M-H, Fixed, 95% CI)	1.73 [1.00, 3.00]	0.05




Fig. 9 The funnel plot of neurological success (A) and secondary surgery at the adjacent level (B). CI, confidence interval.

Discussion

Up to now, CDA application in spinal practice has remained controversial. Whether CDA is superior to ACDF has not been established in the long run ASD is always associated with the length of follow up. Therefore, it is crucial to evaluate the safety and efficiency of CDA in the long run. To our knowledge, there have been several meta-analyses comparing CDA with ACDF. Most of them have included partial long-term results, but they were mixed up with short-term and mid-term results ^{5,16–23}. Therefore, given the availability of newly published long-term results ^{28–38}, we performed this study. This is the first time comparing the

safety and efficiency of CDA with ACDF only focusing on long-term follow-ups.

In our meta-analysis, 11 RCT with more than 5 years' follow-up were identified. Based on the quality assessment criteria recommended by the Cochrane Back Review Group²⁵, all the studies were rated as low risk of bias. However, blinding to patients and care providers was not appropriately achieved in any studies. In addition, only 4 studies^{29,31,32,35} achieved blinding to outcome evaluators. This may result in reporting bias. Heterogeneity definitely existed in the included studies. First, various different types of CDA devices were used in the 11 RCT, including

Kineflex|C²⁹, Bryan^{30,34}, Discover³⁵ Secure-C³⁸, Prestige^{28,31}, Mobi-C^{32,37}, ProDisc-C³³, and PCM³⁶, differing in design and biomechanical properties. Second, the surgical level was different among studies. A total of 8 studies compared one-level CDD^{28–30,32–34,36,38}, 1 study compared two-level CDD³¹, and 2 studies compared both one-level and two-level CDD^{35,37}. Third, the region of studies was also different. Eight studies^{28,29,31,33,34,36–38} were conducted in the US and just 3 studies^{30,32,35} were out of the USA. Fourth, evaluation criteria of outcome measures varied among studies. Thus, we performed a sensitivity analysis including comparing two different effect models, using the leave-one-out method²⁷ and subgroup analysis to find the origin of heterogeneity. The combined results of radiological superior and inferior ASD were not stable and reliable and should be considered with caution. One possible reason is that only 2 studies reported this outcome^{36,37}. Although no publication bias existed in neurological success, publication bias existed in secondary surgery at the adjacent level.

After 5 years' follow up or more, our study revealed that CDA achieved a higher rate of clinical success and better functional outcome measurements with statistical significance, except for NDI score. A mid-term to longterm meta-analysis conducted by Hu et al. 17 compared 4-7 years' clinical results, pooling data from 8 RCT, and showed that CDA achieved a significantly higher clinical success rate and better functional outcome. Similarly, Gao et al.⁵ compared 2–5 years' clinical results, pooling data for 14 RCT for analysis, and found that CDA was superior in VAS pain scores and neurological success, but NDI scores remained similar. In addition, major functional outcome measurements of CDA proved to have no obvious benefits when pooling 1-2 years' data into the analysis²⁴. This difference may originate from the different follow-up duration. Theoretically, CDA shares the same procedure of discectomy, endplate preparing, and decompression. VAS arm pain should be similar. However, VAS arm pain score was favored for CDA at the final follow up.

Adverse events are another major concern when applying CDA. Our results showed no statistical difference in total reported AE, serious AE, and device or surgery-related serious AE. This finding is consistent with some previous metaanalyses^{5,18,23} but contrary to others¹⁷. This difference can be explained by the different inclusion criteria for each study. Our study was focused on the long-term data and only enrolled RCT with more than 5 years' follow-up. Undeniably, pseudoarthrosis would not occur after CDA, but heterotopic ossification and bone loss became new problems^{12,14}. A recent systematic review¹⁴ showed that the long-term heterotopic ossification rate after CDA was 53.6% and the severe (grade 3 and 4) heterotopic ossification rate was 47.5%. In addition, the severe heterotopic ossification rate was significantly associated with follow-up time, with a 0.63% increase per month growth 14. Bone loss was as high as 60.4%, although it did not affect mid-term to long-term clinical outcomes 12. This might be the reason why surgeons did not feel confident recommending CDA as a standard option³⁰. Moreover, it could explain the similar incidence of AE between CDA and ACDF.

Adjacent segment degeneration is the most important factor to be considered. The initial purpose of designing CDA was to prevent ASD after surgery. The biomechanical advantages have been well established 3,49. A recent metaanalysis showed that there was no statistically significant difference in ASD between CDA and ACDF within 24-months' follow-up period, but ASD was significantly lower with an increase of follow-up duration in CDA16. In contrast, Xu et al.21 and Zhu et al.23 found that CDA was superior in reducing the ASD incident rate when compared with ACDF, and this superiority became more apparent over time²¹. Although these 3 studies^{16,21,23} attempted to evaluate ASD and symptomatic ASD separately, the follow-up period was not separated clearly, and long-term results were weak. Our results show that CDA has significantly lower symptomatic ASD. However, when we pooled all data together, there was no statistical difference in radiological superior ASD between CDA and ACDF. Interestingly, Ren et al.20 found that ASD was not significantly different between CDA and ACDF with a smaller sample. Nunley et al. 50 (2018) summarized biomechanical and clinical evidence from worldwide application of CDA and concluded that CDA decreased the rate of radiographic adjacent segment pathology by alleviating adjacentlevel stress. However, the reason why subgroup analysis showed no significant difference in the non-US group is still difficult to explain.

Increased attention has been focused on the secondary surgery rate. Ghobrial et al.40 found that fewer patients with the Bryan disc required surgery for symptomatic ASD when compared with ACDF without statistical significance at 10 years' follow-up. However, they performed combined analysis using Bryan and Prestige artificial discs and found significant differences in symptomatic ASD requiring surgery as early as after 7 years⁴⁰. Surprisingly, MacDowall et al.⁵¹ conducted a retrospective study based on a Swedish database and found that CDA had a similar secondary surgery rate at the adjacent level but a higher secondary surgery rate at the index level with significant difference. However, based on our long-term results, CDA had a significantly lower rate of total secondary surgery, secondary surgery at the adjacent level, and secondary surgery at the index level, which is consistent with mid-term to long-term results¹⁷ However, this finding is contrary to the short-term to mid-term result reported by Zhang et al.⁵² that the secondary surgery rate at the adjacent level showed no significant difference. It seems that CDA exhibited superiority in reducing secondary surgery through restoring favorable physiological biomechanical properties in the long-term follow-up. However, it is important to note that our subgroup analysis also showed no statistical difference in the secondary surgery rate in the non-US group.

Several limitations may exist in this study. First, due to our focus on long-term results, only 11 RCT were included

and 8 of them were conducted in the USA. Therefore, our study may not reflect the worldwide results and may result in bias. In addition, larger size samples are needed in future studies. Second, although all included studies were rated as low risk of bias based on the Cochrane Back Review Group, all of them failed to achieve sufficient blinding and the allocation concealment was rarely clearly described. Third, high heterogeneity exists in NDI score, radiological superior ASD and inferior ASD. Our sensitivity analysis results revealed that radiological superior ASD and inferior ASD were not stable and, therefore, should be considered with caution. Finally, subgroup analysis showed different results for NDI score, symptomatic ASD, total secondary surgery, secondary surgery at the index level, and secondary surgery at the adjacent level between US and non-US regions. Therefore, well-designed worldwide multi-center RCTs with long-term follow-ups are still needed for further evaluation in the future.

Conclusion

Our study provided further evidence that CDA is superior in achieving long-term clinical outcomes such as overall success, NDI success and neurological success, VAS neck pain and arm pain, SF-36 PCS and MCS, symptomatic ASD, total secondary surgery, and secondary surgery at the index level and at the adjacent level. However, no clear benefit could be identified in regard to NDI score, total reported AE, serious AE, device/surgery-related AE, and radiological superior and inferior ASD. Well-designed worldwide RCT with long-term follow up are still necessary for further evaluation in the future.

Acknowledgments

To funding support was received for this study.

References

- **1.** Chin-See-Chong TC, Gadjradj PS, Boelen RJ, Harhangi BS. Current practice of cervical disc arthroplasty: a survey among 383 AOSpine international members. Neurosurg Focus, 2017, 42: E8.
- 2. Hilibrand AS, Robbins M. Adjacent segment degeneration and adjacent segment disease: the consequences of spinal fusion?. Spine J, 2004, 4: 190S–194S.
- **3.** Eck JC, Humphreys SC, Lim TH, et al. Biomechanical study on the effect of cervical spine fusion on adjacent-level intradiscal pressure and segmental motion. Spine (Phila Pa 1976), 2002, 27: 2431–2434.
- **4.** Park DH, Ramakrishnan P, Cho TH, et al. Effect of lower two-level anterior cervical fusion on the superior adjacent level. J Neurosurg Spine, 2007, 7: 336–340.
- Gao F, Mao T, Sun W, et al. An updated meta-analysis comparing artificial cervical disc arthroplasty (CDA) versus anterior cervical discectomy and fusion (ACDF) for the treatment of cervical degenerative disc disease (CDDD). Spine (Phila Pa 1976), 2015, 40: 1816–1823.
- **6.** Duggal N, Pickett GE, Mitsis DK, Keller JL. Early clinical and biomechanical results following cervical arthroplasty. Neurosurg Focus, 2004, 17: E9.
- **7.** Walraevens J, Demaerel P, Suetens P, et al. Longitudinal prospective long-term radiographic follow-up after treatment of single-level cervical disk disease with the Bryan cervical disc. Neurosurgery, 2010, 67: 679–687.
- **8.** McAnany SJ, Overley S, Baird EO, et al. The 5-year cost-effectiveness of anterior cervical discectomy and fusion and cervical disc replacement: a Markov analysis. Spine (Phila Pa 1976), 2014, 39: 1924–1933.
- **9.** Ament JD, Yang Z, Nunley P, Stone MB, Lee D, Kim KD. Cost utility analysis of the cervical artificial disc vs fusion for the treatment of 2-level symptomatic degenerative disc disease: 5-year follow-up. Neurosurgery, 2016, 79: 135–145.
- **10.** Kim JS, Dowdell J, Cheung ZB, *et al.* The seven-year cost-effectiveness of anterior cervical discectomy and fusion versus cervical disc arthroplasty: a Markov analysis. Spine (Phila Pa 1976), 2018, 43: 1543–1551.
- **11.** Overley SC, McAnany SJ, Brochin RL, Kim JS, Merrill RK, Qureshi SA. The 5-year cost-effectiveness of two-level anterior cervical discectomy and fusion or cervical disc replacement: a Markov analysis. Spine J, 2018, 18: 63–71.
- **12.** Heo DH, Lee DC, Oh JY, Park CK. Bone loss of vertebral bodies at the operative segment after cervical arthroplasty: a potential complication?. Neurosurg Focus, 2017, 42: E7.
- ${\bf 13.}\ \ {\rm Wagner}\ {\rm SC},\ {\rm Kang}\ {\rm DG},\ {\rm Helgeson}\ {\rm MD}.\ {\rm Implant}\ {\rm migration}\ {\rm after}\ {\rm Bryan}\ {\rm cervical}\ {\rm disc}\ {\rm arthroplasty}.\ {\rm Spine}\ {\rm J},\ {\rm 2014},\ {\rm 14:}\ {\rm 2513-2514}.$
- **14.** Kong L, Ma Q, Meng F, Cao J, Yu K, Shen Y. The prevalence of heterotopic ossification among patients after cervical artificial disc replacement: a systematic review and meta-analysis. Medicine (Baltimore), 2017, 96: e7163.
- **15.** Saifi C, Fein AW, Cazzulino A, et al. Trends in resource utilization and rate of cervical disc arthroplasty and anterior cervical discectomy and fusion throughout the United States from 2006 to 2013. Spine J, 2018, 18: 1022–1029.
- **16.** Dong L, Xu Z, Chen X, *et al.* The change of adjacent segment after cervical disc arthroplasty compared with anterior cervical discectomy and fusion: a meta-analysis of randomized controlled trials. Spine J, 2017, 17: 1549–1558.
- **17.** Hu Y, Lv G, Ren S, Johansen D. Mid- to long-term outcomes of cervical disc arthroplasty versus anterior cervical discectomy and fusion for treatment of

- symptomatic cervical disc disease: a systematic review and meta-analysis of eight prospective randomized controlled trials. PLoS One, 2016, 11: e0149312.
- **18.** Kan SL, Yuan ZF, Ning GZ, Liu FF, Sun JC, Feng SQ. Cervical disc arthroplasty for symptomatic cervical disc disease: traditional and Bayesian meta-analysis with trial sequential analysis. Int J Surg, 2016, 35: 111–119.
- **19.** Muheremu A, Niu X, Wu Z, Muhanmode Y, Tian W. Comparison of the shortand long-term treatment effect of cervical disk replacement and anterior cervical disk fusion: a meta-analysis. Eur J Orthop Surg Traumatol, 2015, 25: S87–S100.
- 20. Ren C, Song Y, Xue Y, Yang X. Mid- to long-term outcomes after cervical disc arthroplasty compared with anterior discectomy and fusion: a systematic review and meta-analysis of randomized controlled trials. Eur Spine J, 2014, 23: 1115–1123.
- **21.** Xu S, Liang Y, Zhu Z, Qian Y, Liu H. Adjacent segment degeneration or disease after cervical total disc replacement: a meta-analysis of randomized controlled trials. J Orthop Surg Res, 2018, 13: 244.
- **22.** Zhu RS, Kan SL, Cao ZG, Jiang ZH, Zhang XL, Hu W. Secondary surgery after cervical disc arthroplasty versus fusion for cervical degenerative disc disease: a meta-analysis with trial sequential analysis. Orthop Surg, 2018, 10: 181–191.
- **23.** Zhu Y, Zhang B, Liu H, Wu Y, Zhu Q. Cervical disc arthroplasty versus anterior cervical discectomy and fusion for incidence of symptomatic adjacent segment disease: a meta-analysis of prospective randomized controlled trials. Spine (Phila Pa 1976), 2016, 41: 1493–1502.
- **24.** Bartels RH, Donk R, Verbeek AL. No justification for cervical disk prostheses in clinical practice: a meta-analysis of randomized controlled trials. Neurosurgery, 2010, 66: 1153–1160.
- **25.** Furlan AD, Malmivaara A, Chou R, et al. Updated method guideline for systematic reviews in the Cochrane Back and neck group. Spine (Phila Pa 1976), 2015. 40: 1660–1673.
- **26.** Jelicic Kadic A, Vucic K, Dosenovic S, Sapunar D, Puljak L. Extracting data from figures with software was faster, with higher interrater reliability than manual extraction. J Clin Epidemiol, 2016, 74: 119–123.
- **27.** Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol, 2008, 37: 1148–1157.
- **28.** Burkus JK, Traynelis VC, Haid RW Jr, Mummaneni PV. Clinical and radiographic analysis of an artificial cervical disc: 7-year follow-up from the prestige prospective randomized controlled clinical trial: Clinical article. J Neurosurg Spine, 2014, 21: 516–528.
- **29.** Coric \bar{D} , Guyer RD, Nunley PD, et *al.* Prospective, randomized multicenter study of cervical arthroplasty versus anterior cervical discectomy and fusion: 5-year results with a metal-on-metal artificial disc. J Neurosurg Spine, 2018, 28: 252–261.
- **30.** Donk RD, Verbeek ALM, Verhagen WIM, Groenewoud H, Hosman AJF, Bartels R. What's the best surgical treatment for patients with cervical radiculopathy due to single-level degenerative disease? A randomized controlled trial. PLoS One, 2017, 12: e0183603.
- **31.** Gornet MF, Lanman TH, Burkus JK, et al. Two-level cervical disc arthroplasty versus anterior cervical discectomy and fusion: 10-year outcomes of a prospective, randomized investigational device exemption clinical trial. J Neurosurg Spine. 2019. 31: 508–518.

LONG-TERM RESULTS COMPARING CDA AND ACDF

- **32.** Hou Y, Nie L, Pan X, et al. Effectiveness and safety of Mobi-C for treatment of single-level cervical disc spondylosis: a randomised control trial with a minimum of five years of follow-up. Bone Joint J, 2016, 98: 829–833.
- **33.** Janssen ME, Zigler JE, Spivak JM, Delamarter RB, Darden BV 2nd, Kopjar B. ProDisc-C Total disc replacement versus anterior cervical discectomy and fusion for single-level symptomatic cervical disc disease: seven-year follow-up of the prospective randomized U.S. Food and Drug Administration investigational device exemption study. J Bone Joint Surg Am, 2015, 97: 1738–1747.
- **34.** Lavelle WF, Riew KD, Levi AD, Florman JE. Ten-year outcomes of cervical disc replacement with the BRYAN cervical disc: results from a prospective, randomized, controlled clinical trial. Spine (Phila Pa 1976), 2019, 44: 601–608.
- **35.** MacDowall A, Canto Moreira N, Marques C, et al. Artificial disc replacement versus fusion in patients with cervical degenerative disc disease and radiculopathy: a randomized controlled trial with 5-year outcomes. J Neurosurg Spine. 2019. 30: 323–331.
- **36.** Phillips FM, Geisler FH, Gilder KM, Reah C, Howell KM, McAfee PC. Long-term outcomes of the US FDA IDE prospective, randomized controlled clinical trial comparing PCM cervical disc arthroplasty with anterior cervical discectomy and fusion. Spine (Phila Pa 1976), 2015, 40: 674–683.
- **37.** Radcliff K, Davis RJ, Hisey MS, et al. Long-term evaluation of cervical disc arthroplasty with the Mobi-C(c) cervical disc: a randomized, prospective, Multicenter clinical trial with seven-year follow-up. Int J Spine Surg, 2017, 11: 31.
- **38.** Vaccaro A, Beutler W, Peppelman W, et al. Long-term clinical experience with selectively constrained SECURE-C cervical artificial disc for 1-level cervical disc disease: results from seven-year follow-up of a prospective, randomized, controlled investigational device exemption clinical trial. Int J Spine Surg, 2018, 12: 377–387.
- **39.** Delamarter RB, Zigler J. Five-year reoperation rates, cervical total disc replacement versus fusion, results of a prospective randomized clinical trial. Spine (Phila Pa 1976), 2013, 38: 711–717.
- **40.** Ghobrial GM, Lavelle WF, Florman JE, Riew KD, Levi AD. Symptomatic adjacent level disease requiring surgery: analysis of 10-year results from a prospective, randomized, clinical trial comparing cervical disc arthroplasty to anterior cervical fusion. Neurosurgery, 2019, 84: 347–354.
- **41.** Hisey MS, Zigler JE, Jackson R, et al. Prospective, randomized comparison of one-level Mobi-C cervical Total disc replacement vs. anterior cervical discectomy and fusion: results at 5-year follow-up. Int J Spine Surg, 2016, 10: 10.

- **42.** Jackson RJ, Davis RJ, Hoffman GA, *et al.* Subsequent surgery rates after cervical total disc replacement using a Mobi-C cervical disc prosthesis versus anterior cervical discectomy and fusion: a prospective randomized clinical trial with 5-year follow-up. J Neurosurg Spine, 2016, 24: 734–745.
- **43.** Lanman TH, Burkus JK, Dryer RG, Gornet MF, McConnell J, Hodges SD. Long-term clinical and radiographic outcomes of the prestige LP artificial cervical disc replacement at 2 levels: results from a prospective randomized controlled clinical trial. J Neurosurg Spine, 2017, 27: 7–19.
- **44.** Loumeau TP, Darden BV, Kesman TJ, et al. A RCT comparing 7-year clinical outcomes of one level symptomatic cervical disc disease (SCDD) following ProDisc-C total disc arthroplasty (TDA) versus anterior cervical discectomy and fusion (ACDF). Eur Spine J, 2016, 25: 2263–2270.
- **45.** Miller J, Sasso R, Anderson P, Riew KD, McPhilamy A, Gianaris T. Adjacent level degeneration: Bryan Total disc arthroplasty versus anterior cervical discectomy and fusion. Clin Spine Surg, 2018, 31: E98–E101.
- **46.** Radcliff K, Coric D, Albert T. Five-year clinical results of cervical total disc replacement compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial. J Neurosurg Spine, 2016, 25: 213–224.
- **47.** Sasso WR, Smucker JD, Sasso MP, Sasso RC. Long-term clinical outcomes of cervical disc arthroplasty: a prospective, randomized, Controlled Trial. Spine (Phila Pa 1976), 2017, 42: 209–216.
- **48.** Zigler JE, Delamarter R, Murrey D, Spivak J, Janssen M. ProDisc-C and anterior cervical discectomy and fusion as surgical treatment for single-level cervical symptomatic degenerative disc disease: five-year results of a Food and Drug Administration study. Spine (Phila Pa 1976), 2013, 38: 203–209.
- **49.** DiAngelo DJ, Roberston JT, Metcalf NH, McVay BJ, Davis RC. Biomechanical testing of an artificial cervical joint and an anterior cervical plate. J Spinal Disord Tech, 2003, 16: 314–323.
- **50.** Nunley PD, Coric D, Frank KA, Stone MB. Cervical disc arthroplasty: current evidence and real-world application. Neurosurgery, 2018, 83: 1087–1106.
- **51.** MacDowall A, Skeppholm M, Lindhagen L, et al. Artificial disc replacement versus fusion in patients with cervical degenerative disc disease with radiculopathy: 5-year outcomes from the National Swedish Spine Register. J Neurosurg Spine, 2018, 30: 159–167.
- **52.** Zhang Y, Liang C, Tao Y, *et al.* Cervical total disc replacement is superior to anterior cervical decompression and fusion: a meta-analysis of prospective randomized controlled trials. PLoS One, 2015, 10: e0117826.